Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Otsuka Holdings GAAP EPS of ¥142.59, revenue of ¥519.52B; reaffirms FY24 outlook | 3 | Seeking Alpha | ||
09.04. | H LUNDBECK A/S: Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD | 88 | Cision News | ||
03.04. | Otsuka, Click Therapeutics snag FDA clearance for depression therapy app | 199 | FierceBiotech | ||
02.04. | FDA clears first DTx for depression from Otsuka, Click | 3 | pharmaphorum | ||
28.03. | Otsuka and Lundbeck's schizophrenia treatment gains EC approval | 4 | Pharmaceutical Technology | ||
06.03. | Dong-A Otsuka pledges 'zero plastic' on 45th anniversary | 3 | Korea Herald | ||
26.02. | iBio, Inc.: iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka | 683 | GlobeNewswire (Europe) | - Deal includes $1 million upfront and potential future milestone payments - - iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates - BRYAN... ► Artikel lesen | |
19.02. | FDA grants breakthrough therapy status for Otsuka's IgAN drug | 3 | Pharmaceutical Business Review | ||
16.02. | Otsuka wins FDA breakthrough therapy designation for IgAN drug | 2 | Pharmaceutical Technology | ||
13.02. | Otsuka's Alzheimer's drug AVP-786 fails phase 3 trial | 4 | Investing.com | ||
08.02. | Otsuka's Abilify Maintena: dual drug expiry signals sales decline | 1 | Pharmaceutical Technology | ||
01.02. | Otsuka Corporation GAAP EPS of ¥297.99, revenue of ¥1.47B | 2 | Seeking Alpha | ||
19.12.23 | Otsuka pays $65M cash for European rights to Ionis' phase 3 rare disease med | 7 | FierceBiotech | ||
19.12.23 | Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka | 7 | Zacks | ||
19.12.23 | Ionis and Otsuka sign agreement for hereditary angioedema therapy | 5 | Pharmaceutical Technology | ||
18.12.23 | Ionis Pharmaceuticals enters into a license agreement with Otsuka | 8 | Seeking Alpha | ||
11.12.23 | Otsuka sees highest patent filings and grants during July in Q3 2023 | 4 | Pharmaceutical Technology | ||
01.12.23 | Otsuka Buys US Supplement Maker Bonafide Health for $425 Million | 4 | BNN Bloomberg | ||
14.11.23 | Otsuka Pharmaceutical submits NDA for voclosporin in Japan | 5 | Pharmaceutical Business Review | ||
13.11.23 | FDA rules Otsuka marketing claim overstates Rexulti efficacy, threatening cornerstone of huge TV push | 2 | FiercePharma |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 634 |
BAYER | 442 |
BYD | 358 |
NEL | 338 |
NVIDIA | 320 |
TESLA | 299 |
DEUTSCHE BANK | 295 |
TUI | 291 |
PLUG POWER | 288 |
SUPER MICRO COMPUTER | 268 |
APPLE | 255 |
RHEINMETALL | 247 |
RWE | 238 |
MERCEDES-BENZ | 229 |
DEUTSCHE LUFTHANSA | 214 |
AMAZON | 210 |
BERKSHIRE HATHAWAY | 206 |
RENK GROUP | 170 |
COMMERZBANK | 168 |
BIONTECH | 167 |
VOLKSWAGEN | 166 |
ALLIANZ | 164 |
AIXTRON SE | 163 |
PAYPAL | 161 |
BASF | 160 |